|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104909 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-25 11:21:09 |
|
注册时间: Date of Registration: |
2025-06-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
超声引导下胸腰筋膜内注射多聚脱氧核糖核苷酸治疗成人下腰痛的双盲随机对照试验 |
|
Public title: |
A Double-Blind Randomized Controlled Trial of Polydeoxyribonucleotide Injection into the Thoracolumbar Fascia under Ultrasound Guidance for the Treatment of Low Back Pain in Adults |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
超声引导下胸腰筋膜内注射多聚脱氧核糖核苷酸治疗成人下腰痛的双盲随机对照试验 |
|
Scientific title: |
A Double-Blind Randomized Controlled Trial of Polydeoxyribonucleotide Injection into the Thoracolumbar Fascia under Ultrasound Guidance for the Treatment of Low Back Pain in Adults |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吉睿 |
研究负责人: |
高博 |
|
Applicant: |
Ji Rui |
Study leader: |
Gao bo |
|
申请注册联系人电话: Applicant telephone: |
+86 184 3599 8852 |
研究负责人电话:
Study leader's |
+86 135 7280 1499 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
jirui8852@163.com |
研究负责人电子邮件: Study leader's E-mail: |
gaobofmmu@hotmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
陕西省西安市新城区长乐西路169号 |
研究负责人通讯地址: |
陕西省西安市新城区长乐西路169号 |
|
Applicant address: |
No. 169, Changle West Road, Xincheng District, Xi'an, Shaanxi |
Study leader's address: |
No. 169, Changle West Road, Xincheng District, Xi'an, Shaanxi |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
空军军医大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Air Force Medical University |
||
|
研究负责人所在单位: |
空军军医大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Air Force Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
KY20252180-F-1号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军空军军医大学第一附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the first Afficiated Hospital of the Air Force Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-27 00:00:00 | ||
|
伦理委员会联系人: |
伍晓晓 |
||
|
Contact Name of the ethic committee: |
Wu Xiaoxiao |
||
|
伦理委员会联系地址: |
陕西省西安市新城区长乐西路127号 |
||
|
Contact Address of the ethic committee: |
No. 127, Changle West Road, Xincheng District, Xi'an, Shaanxi |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 29 8477 1794 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
空军军医大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Air Force Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
陕西省西安市新城区长乐西路169号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 169, Changle West Road, Xincheng District, Xi'an, Shaanxi |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家自然基金委优秀青年项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Excellent Young Scientists Fund of the National Natural Science Foundation of China |
||||||||||||||||||||||
|
研究疾病: |
腰背痛 |
||||||||||||||||||||||
|
Target disease: |
Low back pain |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本研究通过对比评估超声引导下于胸腰筋膜内注射多聚脱氧核糖核苷酸(Polydeoxyribonucleotide,PDRN)或安慰剂后患者改善情况,评估PDRN对治疗成人肌肉和筋膜源性下腰痛患者症状和功能的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
This study evaluated the effects of Polydeoxyribonucleotide (PDRN) on symptoms and function in adult patients with myofascial low back pain by comparing the improvements in patients after ultrasound-guided injections of PDRN or placebo into the thoracolumbar fascia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1、符合肌肉和筋膜源性下腰痛的诊断标准; 2、中等至重度疼痛,视觉模拟评分法(VAS)>=4分; 3、患者年龄在18岁至65岁之间; 4、发病时间超过1个月; 5、患者详细了解研究的相关内容,具有良好的依从性和较高的配合度; 6、已签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria for myofascial low back pain; 2. Moderate to severe pain, with a Visual Analog Scale (VAS) score > =4; 3. Patients are aged between 18 and 65 years; 4. Duration of symptoms exceeds one month; 5. Patients have a thorough understanding of the study content, with good compliance and high level of cooperation; 6. Informed consent has been signed. |
||||||||||||||||||||||
|
排除标准: |
1、因任何其他原因导致的下腰痛,包括但不限于腰椎间盘突出症、腰椎管狭窄、强直性脊柱炎、脊柱肿瘤、脊柱结核、脊髓感染等; 2、严重糖尿病及药物过敏者; 3、发热、上呼吸道感染或患有其他感染性疾病者; 4、患有全身性疾病或脏器功能不全者; 5、凝血功能障碍或服用抗凝药物者; 6、注射部位或附近软组织感染者; 7、目前使用类固醇类药物或正在接受其他可能影响本研究观察指标的相关治疗者; 8、严重精神疾病等不能配合者; 9、怀孕或哺乳期女性。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Low back pain caused by any other reasons, including but not limited to lumbar disc herniation, lumbar spinal stenosis, ankylosing spondylitis, spinal tumors, spinal tuberculosis, spinal cord infections, etc.; 2. Patients with severe diabetes or drug allergies; 3. Patients with fever, upper respiratory tract infections, or other infectious diseases; 4. Patients with systemic diseases or organ dysfunction; 5. Patients with coagulation disorders or those taking anticoagulant medications; 6. Patients with infections of the injection site or surrounding soft tissues; 7. Patients currently using corticosteroids or undergoing other treatments that may affect the observation indicators of this study; 8. Patients with severe mental illness who cannot cooperate; 9. Pregnant or breastfeeding women. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-06-01 00:00:00至 To 2026-06-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-08-01 00:00:00 至 To 2026-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
应用 SAS 统计软件编程,给定种子数,产生 40 例受试者治疗分配(PDRN 组和安慰剂组)的随机安排,所设定的种子数等参数记录在盲底中。随机化名单由一位既不是招募人员也不是治疗人员的研究者准备。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The SAS statistical software was used to program the random assignment of 40 subjects to treatment groups (PDRN group and placebo group) with a given seed number. The seed number and other parameters were recorded in the blind code. The randomization list was prepared by a researcher who was neither involved in recruitment nor in treatment administration. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
双盲 |
|
Blinding: |
Double-blind |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
论文发表后半年内,www.medresman.org。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Within half a year after the publication of the paper, www.medresman.org. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
采用病例记录表进行数据管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form were used for data management |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |